drugset / Trial / NCT04799639
Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety and efficacy of Sindilimab combined with Paclitaxel and Cisplatin in neoadjuvant chemotherapy for Locally Advanced Cervical Cancer
Timeline
- Start
- 2021-03-18
- Primary completion
- 2024-06-17
- Completion
- 2024-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Sindilimab | Unknown | 200 mg | Intravenous |
| Subject | cisplantin | Unknown | 70 mg/m2 | Intravenous |